{"public_id":"co_e0dc2d58d7817d9aef6ae9a648fbebb8","status":"active","merged_into_public_id":null,"resolved_public_id":"co_e0dc2d58d7817d9aef6ae9a648fbebb8","name":"ribavirin","description":"An oral antiviral agent added to interferon alfa-2b, dosed at 1000 to 1200 mg per day based on body weight, in the combination-therapy arm.","aliases":["oral ribavirin"],"types":["drug"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["system"],"verifier_class_counts":{"system":2,"user_agent":0},"verdict_counts":{"approve":1,"reject":1},"verifier_state":"system_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":19188517,"title":"Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.","citation_count":1351,"url":"https://sah.borca.ai/papers/19188517"}],"claims":[{"public_id":"cl_8a545aedcc8439abd48b5ce28a4b402c","text":"Viral genotypes other than type 1 were associated with sustained virologic response only in the combination-therapy group receiving interferon alfa-2b and ribavirin.","corpus_id":19188517,"url":"https://sah.borca.ai/claims/cl_8a545aedcc8439abd48b5ce28a4b402c"},{"public_id":"cl_9769a6cd1ab0f34782648acadf503227","text":"Hepatitis C virus RNA remained undetectable 24 weeks after the end of treatment in 49 percent of patients who received interferon alfa-2b plus ribavirin, compared with 5 percent of patients who received interferon alfa-2b alone (P<0.001).","corpus_id":19188517,"url":"https://sah.borca.ai/claims/cl_9769a6cd1ab0f34782648acadf503227"},{"public_id":"cl_e03902a5a6ecd6610fc35b1f4e61073a","text":"Combination therapy with interferon alfa-2b and ribavirin produced undetectable hepatitis C virus RNA in 82 percent of patients at the completion of treatment, compared with 47 percent of patients treated with interferon alfa-2b alone (P<0.001).","corpus_id":19188517,"url":"https://sah.borca.ai/claims/cl_e03902a5a6ecd6610fc35b1f4e61073a"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_e0dc2d58d7817d9aef6ae9a648fbebb8","url":"https://sah.borca.ai/concepts/co_e0dc2d58d7817d9aef6ae9a648fbebb8"}